Cargando…
A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis
Extensively drug-resistant A. baumannii (XDRAB) pneumonia has a high mortality rate in hospitalized patients. One of the recommended treatments is colistin combined with sulbactam; however, the optimal dosage of sulbactam is unclear. In an open-label, superiority, randomized controlled trial, patien...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405071/ https://www.ncbi.nlm.nih.gov/pubmed/36009980 http://dx.doi.org/10.3390/antibiotics11081112 |
_version_ | 1784773790440357888 |
---|---|
author | Ungthammakhun, Chutchawan Vasikasin, Vasin Changpradub, Dhitiwat |
author_facet | Ungthammakhun, Chutchawan Vasikasin, Vasin Changpradub, Dhitiwat |
author_sort | Ungthammakhun, Chutchawan |
collection | PubMed |
description | Extensively drug-resistant A. baumannii (XDRAB) pneumonia has a high mortality rate in hospitalized patients. One of the recommended treatments is colistin combined with sulbactam; however, the optimal dosage of sulbactam is unclear. In an open-label, superiority, randomized controlled trial, patients diagnosed with XDRAB pneumonia were randomly assigned (1:1) to receive colistin in combination with sulbactam at either 9 g/day or 12 g/day. The primary outcome was the 28-day mortality rate in the intention-to-treat population. A total of 88 patients received colistin in combination with sulbactam at a dosage of either 12 g/day (n = 45) or 9 g/day (n = 43). Trends toward a lower mortality rate were observed in the 12 g/day group at 7 days (11.1% vs. 23.3%), 14 days (33.3% vs. 41.9%), and 28 days (46.7% vs. 58.1%). The microbiological cure rate at day 7 was significantly higher in the 12 g/day group (90.5% vs. 58.1%; p = 0.02). Factors associated with mortality at 28 days were asthma, cirrhosis, APACHEII score ≥ 28, and a dosage of sulbactam of 9 g/day for mortality at any timepoint. Treatment with colistin combined with sulbactam at 12 g/day was not superior to the combination treatment with sulbactam at 9 g/day. However, due to being an interim analysis, this trial was underpowered to detect mortality differences. |
format | Online Article Text |
id | pubmed-9405071 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94050712022-08-26 A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis Ungthammakhun, Chutchawan Vasikasin, Vasin Changpradub, Dhitiwat Antibiotics (Basel) Article Extensively drug-resistant A. baumannii (XDRAB) pneumonia has a high mortality rate in hospitalized patients. One of the recommended treatments is colistin combined with sulbactam; however, the optimal dosage of sulbactam is unclear. In an open-label, superiority, randomized controlled trial, patients diagnosed with XDRAB pneumonia were randomly assigned (1:1) to receive colistin in combination with sulbactam at either 9 g/day or 12 g/day. The primary outcome was the 28-day mortality rate in the intention-to-treat population. A total of 88 patients received colistin in combination with sulbactam at a dosage of either 12 g/day (n = 45) or 9 g/day (n = 43). Trends toward a lower mortality rate were observed in the 12 g/day group at 7 days (11.1% vs. 23.3%), 14 days (33.3% vs. 41.9%), and 28 days (46.7% vs. 58.1%). The microbiological cure rate at day 7 was significantly higher in the 12 g/day group (90.5% vs. 58.1%; p = 0.02). Factors associated with mortality at 28 days were asthma, cirrhosis, APACHEII score ≥ 28, and a dosage of sulbactam of 9 g/day for mortality at any timepoint. Treatment with colistin combined with sulbactam at 12 g/day was not superior to the combination treatment with sulbactam at 9 g/day. However, due to being an interim analysis, this trial was underpowered to detect mortality differences. MDPI 2022-08-17 /pmc/articles/PMC9405071/ /pubmed/36009980 http://dx.doi.org/10.3390/antibiotics11081112 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ungthammakhun, Chutchawan Vasikasin, Vasin Changpradub, Dhitiwat A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title | A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title_full | A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title_fullStr | A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title_full_unstemmed | A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title_short | A Randomized Controlled Trial of Colistin Combined with Sulbactam: 9 g per Day versus 12 g per Day in the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Pneumonia: An Interim Analysis |
title_sort | randomized controlled trial of colistin combined with sulbactam: 9 g per day versus 12 g per day in the treatment of extensively drug-resistant acinetobacter baumannii pneumonia: an interim analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405071/ https://www.ncbi.nlm.nih.gov/pubmed/36009980 http://dx.doi.org/10.3390/antibiotics11081112 |
work_keys_str_mv | AT ungthammakhunchutchawan arandomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis AT vasikasinvasin arandomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis AT changpradubdhitiwat arandomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis AT ungthammakhunchutchawan randomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis AT vasikasinvasin randomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis AT changpradubdhitiwat randomizedcontrolledtrialofcolistincombinedwithsulbactam9gperdayversus12gperdayinthetreatmentofextensivelydrugresistantacinetobacterbaumanniipneumoniaaninterimanalysis |